Issue of Equity

CRISM Therapeutics Corporation

15 October 2026

 

15 October 2026

CRISM Therapeutics Corporation

(‘CRISM’, ‘CRISM Therapeutics’ or the ‘Company’)

Issue of Equity

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces it has entered into a subscription agreement, pursuant to which it will issue 472,222 new ordinary shares of no par value each in the Company (the “New Ordinary Shares") at a price of 9 pence per share, to a consultant.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the New Ordinary Shares ("Admission"). It is expected that Admission will become effective and that trading will commence in the New Ordinary Shares at 8.00 a.m. on or around 20 October 2026. The New Ordinary Shares will rank pari passu with the Company's existing ordinary shares of no par value (“Ordinary Shares”).

Following the issue of the New Ordinary Shares, the total issued share capital of the Company will consist of 79,657,488 Ordinary Shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company will be 79,657,488 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, CEO Chris McConville, CSO	David Hignell Vadim Alexandre Adam Cowl	Henry Harrison Topham Jamie Hooper [e-mail]
via Burson Buchanan	[phone]	[phone]

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM has commenced recruitment at the Company’s first clinical site for its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

 

END